Protara Therapeutics prices public offering of 13M shares at $5.75 for $75M gross proceeds

Protara Therapeutics, Inc.

Priced 13,043,479 common shares at $5.75 per share; gross proceeds ~$75M before fees.
Underwriters granted 30-day option to buy up to 1,956,521 additional shares at same price.
Net proceeds to fund clinical development of TARA-002 and other pipeline programs.
Company and insiders subject to 60-day lock-up on share transfers post-offering.
Offering closed Dec 8, 2025; J.P. Morgan, TD Securities, Piper Sandler acted as representatives.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Protara Therapeutics, Inc. entered into Underwriting Agreement with J.P. Morgan Securities LLC, TD Securities (USA) LLC and Piper Sandler & Co., as representatives of the several underwriters valued at approximately $75 million (effective 2025-12-04).

Action: entry
Agreement: underwriting
Counterparty: J.P. Morgan Securities LLC, TD Securities (USA) LLC and Piper Sandler & Co., as representatives of the several underwriters
Value: approximately $75 million
Effective: 2025-12-04

Exact text from the filing

On December 4, 2025, Protara Therapeutics, Inc. (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC, TD Securities (USA) LLC and Piper Sandler & Co., as representatives (the “Representatives”) of the several underwriters named therein (collectively, the “Underwriters”), pursuant to which the Company agreed to sell and issue to the Underwriters an aggregate of 13,043,479 shares (the “Shares”) of common stock of the Company, par value $0.001 per share (the “Common Stock”) (the “Offering”).

View on SEC.gov

Browse all material agreements →

Protara Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-25-119242

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.